Table 1.

Description of studies in the systematic review and reported measures of test accuracy

Study	Year	Country	Prospective data collection	Double or single blinding	Index test used	Specific details of index test used	Number of patients	Specimens per patient	Reference standard	Reported sensitivity	Reported specificity
Khan et al. [41]	2013	Pakistan	Yes	No	In-house	Real Time PCR IS6110, MPB-64, 16rRNA	50	3 CMUS	A	88·6	96·5
Garcia-Elorriaga et al. [42]	2009	Mexico	No	No	In-house	Nested PCR 32-kDa, MTP40 and IS6110	20	1	a	100	82
Khosravi et al. [43]	2010	Iran	Yes	No	In-house	Nested PCR IS6110	200	1	A	100	100
Raghavendran et al. [44]	2016	India	Yes	No	In-house	PCR (gene target nor reported)	48	1	A	89·5	89·6
Hemal et al. [45]	2000	India	Yes	No	In-house	PCR MPB-64	42	Unknown	b	94·3	85·7
van Vollenhoven et al. [46]	1996	South Africa	Yes	No	In-house	PCR M13 mp8	82	Unknown	A	100	100
Moussa et al. [47]	2000	Egypt	Yes	No	In-house	PCR 16S rRNA	1000	3 CMUS	A	87·05	98·9
Moussa et al. [47]	2000	Egypt	Yes	No	In-house	PCR IS6110	1000	3 CMUS	A	95·59	98·11
Gamboa et al. [48]	1998	Colombia	Yes	No	Commercial	LCx M. Tuberculosis Assay	69	Unknown	A	70	100
Hillerman et al. [49]	2011	Germany	Yes	Yes	Commercial	Xpert MTB/RIF	91	1	A	100	98.6
Tortoli et al. [50]	2012	Italy	Yes	Yes	Commercial	Xpert MTB/RIF	130	1	B	87·5	99·1

CMUS continuous day- morning urine sample, A microbiological reference standard (positive culture), B broad reference standard (either a positive culture or clinical manifestations with adequate treatment response after a minimum one-month follow-up); ^aFinal Physician Decision considering culture and treatment response; ^badvanced and typical radiologic findings, positive urine smear or culture, and histologic examination of a biopsy or surgically resected specimen